Abstract: A cushion material with improved vibration absorptivity, and a cushion material manufacturing method for easily obtaining the cushion material are provided. The cushion material (1) includes a foam body (2) having a surface portion (20) formed of an air permeability control surface portion (21) and an air permeability uncontrol surface portion (22), and a covering material (3) configured to cover the air permeability uncontrol surface portion (22). The cushion material manufacturing method is a cushion material manufacturing method for obtaining the cushion material (1), and includes covering the air permeability uncontrol surface portion (22) of the foam body (2) with the covering material (3).

Abstract: A seat pad with improved thermal comfort and improved vibration absorptivity and a seat pad manufacturing method for easily obtaining the seat pad are provided. In the seat pad (1), when a surface portion (2) up to 10 mm from a surface (1f) is cut out and the air permeability AR1 of the surface portion (2) is measured in compliance with JIS K 6400, the air permeability AR1 is more than 5 cc/cm2/sec and 25 cc/cm2/sec or less. The seat pad manufacturing method is a seat pad manufacturing method for obtaining the seat pad (1) by supplying a molding material into a molding die and performing foam molding. As the molding die, a molding die an inner surface of which is covered with polystyrene or polyethylene is used.

Abstract: A driving operation handover system includes a memory and a processor, wherein the processor is configured to: acquire a first characteristic value of preset setting characteristics during travel of a vehicle equipped with a manual operation unit that an occupant operates; acquire a second characteristic value of the preset setting characteristics during travel of a virtual vehicle that simulates the vehicle, which a remote operator operates using a remote operation unit; calculate a difference value between the first characteristic value and the second characteristic value; in a case in which the difference value is lower than a setting threshold value, notify the occupant and the remote operator that operation of the vehicle can be handed over; and after notification, switch operation of the vehicle from one of the remote operator or the occupant to another of the remote operator or the occupant.

Abstract: A remote operation system includes a processor that is configured to acquire position information and communication quality information from each of plural vehicles on a regular basis, create position-specific communication quality information in which the position information and the communication quality information are associated with each other, supply the position-specific communication quality information to an operator of a remote operation target vehicle.

Abstract: Provided is a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of diseases involving ATX. A carboxylic acid compound represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.

Abstract: Provided are a negative electrode that is for use in a non-aqueous electrolyte secondary battery, includes a porous metal body as a current collector, contains a skeleton-forming agent highly infiltrated in the current collector so that It is less likely to suffer from structural degradation and provides improved cycle durability; and a non-aqueous electrolyte secondary battery including such a negative electrode. The negative electrode for use in a non-aqueous electrolyte secondary battery includes a current collector including a porous metal body; a first negative electrode material disposed in pores of the porous metal body and including a conductive aid, a binder, and a negative electrode active material including a silicon-based material; and a second negative electrode material disposed in pores of the porous metal body and including a skeleton-forming agent including a silicate having a siloxane bond.

Abstract: To provide a negative electrode for nonaqueous electrolyte secondary batteries, by which durability deterioration and structural deterioration of the electrode is suppressed, and cycle durability and energy density can be improved by suppressing generation of voids in the inside of the porous metal, and a nonaqueous electrolyte secondary battery including the same. A negative electrode for nonaqueous electrolyte secondary batteries, having a current collector made of porous metal, and a negative electrode material placed in pores of the porous metal, the negative electrode material including a first negative electrode active material placed on an internal surface of each of the pores and including a silicon-based material; a skeleton forming agent placed on the first negative electrode active material and including a silicate having a siloxane bond; and a second negative electrode active material placed on the skeleton forming agent.

Abstract: To provide a nonaqueous electrolyte secondary battery which enables to suppress durability deterioration, improve energy density, and further suppress a decrease in the function of the nonaqueous electrolyte secondary battery cell. A nonaqueous electrolyte secondary battery, comprising: a positive electrode; and a negative electrode, wherein the negative electrode has: a current collector comprising a porous metal body; and a negative electrode material disposed in pores of the porous metal body, the negative electrode material comprises a negative electrode active material comprising a silicon-based material, a skeleton-forming agent comprising a silicate having a siloxane bond, a conductive auxiliary, and a binder, and a content of the skeleton-forming agent in an outside in a surface direction of the negative electrode is higher than a content of the skeleton-forming agent in an inside in the surface direction of the negative electrode.

Abstract: A product design system includes a first transmitting section that uses a look-up table to convert second design image data for which image correction is completed into third design image data of a color space that is represented with a thermochromic material, and transmits the third design image data derived from the conversion to an external apparatus, and a second transmitting section that transmits a decorating request based on fourth design image data that is profile-transformed from the second design image data to a decorating apparatus.

Abstract: Imaging devices and electronic apparatuses incorporating imaging devices or image pick-up elements are provided. An imaging device as disclosed can include a substrate, a first opto-electronic converter having a first area formed in the substrate, and a second opto-electronic converter having a second area formed in the substrate. The first area is larger than the second area. In addition, a light blocking wall can extend from a first surface of the substrate such that at least a portion of the light blocking wall is between the first opto-electronic converter and the second opto-electronic converter.

Abstract: Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.

Abstract: Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.

Abstract: Provided is a heterocyclic derivative showing a thyroid hormone ? receptor agonist action, which is effective for the prophylaxis or treatment of the diseases relating to the action. A compound represented by the formula [I]: wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, and a medicament containing the compound as an active ingredient.

Abstract: Provided is a heterocyclic derivative showing a thyroid hormone ? receptor agonist action, which is effective for the prophylaxis or treatment of the diseases relating to the action. A compound represented by the formula [I]: wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, and a medicament containing the compound as an active ingredient.

Abstract: Provided is a heterocyclic derivative showing a thyroid hormone ? receptor agonist action, which is effective for the prophylaxis or treatment of the diseases relating to the action. A compound represented by the formula [I]: wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, and a medicament containing the compound as an active ingredient.

Abstract: The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction.

Abstract: The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction.